Company news
Maia Biotechnology, Inc. (AMEX:MAIA) news
Every Maia Biotechnology, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026
September 10, 2026
MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion
June 3, 2026
MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual ...
June 1, 2026
MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targ...
April 16, 2026
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Antic...
April 8, 2026
MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lu...
March 31, 2026
MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock
March 4, 2026
MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock
March 2, 2026
MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
March 2, 2026
MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market
February 24, 2026
MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum
January 20, 2026
MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings
December 24, 2025
MAIA Biotechnology Announces $1.51 Million Private Placement
December 16, 2025
MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Adv...
December 11, 2025
MAIA Biotechnology Announces Open Market Purchases by CEO and Directors
December 1, 2025
MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025
November 21, 2025
MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania’s 2025 Smart Diaspora Conference on Oncology Research and Innovation
November 20, 2025
MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer ...
October 27, 2025
MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
October 23, 2025
MAIA Biotechnology Announces $736,600 Private Placement
October 13, 2025
MAIA Biotechnology Announces $2.25 Million Private Placement
September 29, 2025
MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent
September 24, 2025
MAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
September 11, 2025
MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer
September 5, 2025
MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells
August 27, 2025
MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy
August 13, 2025
MAIA Biotechnology Receives FDA’s Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer
July 28, 2025
MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer T...
July 17, 2025
MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer
July 9, 2025
MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress
July 1, 2025
MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board
June 24, 2025
MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies
June 18, 2025
MAIA Biotechnology to Present at BIO International Convention 2025
June 10, 2025
MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial
June 5, 2025
MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer
June 5, 2025
CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000
May 27, 2025
MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
May 15, 2025
MAIA Biotechnology Announces Director Participation in Recent Private Placement
May 14, 2025
CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement
May 5, 2025
MAIA Biotechnology Announces $1.08 Million Private Placement
May 5, 2025